hydralazine has been researched along with Anoxemia in 15 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we have evaluated the potential of one such agent under study, namely hydralazine, which was shown earlier to enhance hypoxia inducible factor-1α (HIF-1α) levels in experimental animal systems." | 7.75 | Hypoxic pre-conditioning in a rat renal ischemia model: an evaluation of the use of hydralazine. ( Chander, P; Choudhury, M; Dorai, T; Grasso, M; Michels, C, 2009) |
| "To evaluate the potency of vasodilatory drugs in hypoxia, we studied the effects of nitroglycerin (NTG), prostaglandin E1 (PGE1), and hydralazine on porcine coronary artery constricted with endothelin-1 (ET-1) in both oxygenated and hypoxic conditions." | 7.69 | Hypoxia modifies the vasodilatory effects of nitroglycerin, prostaglandin E1, and hydralazine on isolated porcine coronary arteries. ( Fujihara, H; Fujiwara, N; Fukuda, S; Sakuma, K; Shimoji, K; Tanaka, T; Toriumi, T; Tsukui, A, 1994) |
| "Administration of hydralazine in patients with pulmonary hypertension has been reported to cause excessive systemic vasodilatation, limiting its clinical utility (N Engl J Med 1982; 306: 1326)." | 7.67 | Continuous, low dose of hydralazine, reduces acute hypoxic pulmonary hypertension without a corresponding fall in systemic arterial pressure. ( Kobayashi, T; Yoshimura, K, 1986) |
| " In this study, we have evaluated the potential of one such agent under study, namely hydralazine, which was shown earlier to enhance hypoxia inducible factor-1α (HIF-1α) levels in experimental animal systems." | 3.75 | Hypoxic pre-conditioning in a rat renal ischemia model: an evaluation of the use of hydralazine. ( Chander, P; Choudhury, M; Dorai, T; Grasso, M; Michels, C, 2009) |
| "To evaluate the potency of vasodilatory drugs in hypoxia, we studied the effects of nitroglycerin (NTG), prostaglandin E1 (PGE1), and hydralazine on porcine coronary artery constricted with endothelin-1 (ET-1) in both oxygenated and hypoxic conditions." | 3.69 | Hypoxia modifies the vasodilatory effects of nitroglycerin, prostaglandin E1, and hydralazine on isolated porcine coronary arteries. ( Fujihara, H; Fujiwara, N; Fukuda, S; Sakuma, K; Shimoji, K; Tanaka, T; Toriumi, T; Tsukui, A, 1994) |
| "Administration of hydralazine in patients with pulmonary hypertension has been reported to cause excessive systemic vasodilatation, limiting its clinical utility (N Engl J Med 1982; 306: 1326)." | 3.67 | Continuous, low dose of hydralazine, reduces acute hypoxic pulmonary hypertension without a corresponding fall in systemic arterial pressure. ( Kobayashi, T; Yoshimura, K, 1986) |
| "In contrast, N2 breathing to terminal anoxia and intravenous hydralazine produced a negligible increase in Hb, but large reductions in HbO and HbT." | 1.33 | The effects of tumour blood flow and oxygenation modifiers on subcutaneous tumours as determined by NIRS. ( Connelly, JP; Griffiths, JR; Howe, FA; Robinson, SP; Springett, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (53.33) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Voirin, AC | 1 |
| Chatard, M | 2 |
| Briançon-Marjollet, A | 1 |
| Pepin, JL | 1 |
| Perek, N | 2 |
| Roche, F | 2 |
| Kawaguchi, A | 1 |
| Isayama, T | 1 |
| Mori, R | 1 |
| Minami, H | 1 |
| Yang, Y | 1 |
| Tamura, M | 1 |
| Puech, C | 1 |
| Michels, C | 1 |
| Dorai, T | 1 |
| Chander, P | 1 |
| Choudhury, M | 1 |
| Grasso, M | 1 |
| KIRPEKAR, SM | 1 |
| LEWIS, JJ | 1 |
| Howe, FA | 1 |
| Connelly, JP | 1 |
| Robinson, SP | 1 |
| Springett, R | 1 |
| Griffiths, JR | 1 |
| Rubin, LJ | 1 |
| Bishop, MJ | 1 |
| Kennard, S | 1 |
| Artman, LD | 1 |
| Cheney, FW | 1 |
| Rüegger, M | 1 |
| Medici, TC | 1 |
| Stanbrook, HS | 1 |
| Morris, KG | 1 |
| McMurtry, IF | 1 |
| Fukuda, S | 1 |
| Sakuma, K | 1 |
| Tsukui, A | 1 |
| Fujiwara, N | 1 |
| Tanaka, T | 1 |
| Fujihara, H | 1 |
| Toriumi, T | 1 |
| Shimoji, K | 1 |
| Abakumov, GZ | 1 |
| Lukienko, PI | 1 |
| Canby, CA | 1 |
| Tomanek, RJ | 1 |
| Bell, JM | 1 |
| Whitmore, WL | 1 |
| Slotkin, TA | 1 |
| Yoshimura, K | 1 |
| Kobayashi, T | 1 |
2 reviews available for hydralazine and Anoxemia
| Article | Year |
|---|---|
Hydralazine in infants with persistent hypoxemic respiratory failure.
Topics: Antihypertensive Agents; Humans; Hydralazine; Hypoxia; Infant; Infant, Newborn; Infant, Premature; R | 2013 |
Cardiovascular effects of vasodilator therapy for pulmonary arterial hypertension.
Topics: Cardiac Output; Echocardiography; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Hypote | 1983 |
13 other studies available for hydralazine and Anoxemia
| Article | Year |
|---|---|
Loss of Blood-Brain Barrier Integrity in an In Vitro Model Subjected to Intermittent Hypoxia: Is Reversion Possible with a HIF-1α Pathway Inhibitor?
Topics: Astrocytes; Blood-Brain Barrier; Endothelial Cells; Humans; Hydralazine; Hypoxia | 2023 |
Hypoxic Stress Induced by Hydralazine Leads to a Loss of Blood-Brain Barrier Integrity and an Increase in Efflux Transporter Activity.
Topics: Animals; Biological Transport; Biomarkers; Blood-Brain Barrier; Cell Survival; Hydralazine; Hypoxia; | 2016 |
Hypoxic pre-conditioning in a rat renal ischemia model: an evaluation of the use of hydralazine.
Topics: Animals; Blood Urea Nitrogen; Disease Models, Animal; Hydralazine; Hypoxia; Hypoxia-Inducible Factor | 2009 |
Antagonism to the actions of hydrallazine, reserpine, potassium cyanide, sodium azide and anoxia on arterial smooth muscle.
Topics: Arteries; Azides; Carbohydrate Metabolism; Carbohydrates; Cyanides; Fats; Hydralazine; Hypoxia; Lipi | 1958 |
The effects of tumour blood flow and oxygenation modifiers on subcutaneous tumours as determined by NIRS.
Topics: Animals; Carbon Dioxide; Female; Hemoglobins; Hydralazine; Hyperoxia; Hypoxia; Magnetic Resonance Im | 2005 |
Hydralazine does not inhibit canine hypoxic pulmonary vasoconstriction.
Topics: Animals; Blood Pressure; Cardiac Output; Dogs; Hydralazine; Hypoxia; Nitroprusside; Pulmonary Artery | 1983 |
[New therapies for cor pulmonale?].
Topics: Bloodletting; Humans; Hydralazine; Hypertension, Pulmonary; Hypoxia; Iron; Lung Diseases, Obstructiv | 1983 |
Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists.
Topics: Animals; Dimethyl Sulfoxide; Hydralazine; Hypertension, Pulmonary; Hypoxia; Male; Nifedipine; Pulmon | 1984 |
Hypoxia modifies the vasodilatory effects of nitroglycerin, prostaglandin E1, and hydralazine on isolated porcine coronary arteries.
Topics: Alprostadil; Analysis of Variance; Animals; Coronary Vessels; Cyclic AMP; Cyclic GMP; Endothelins; H | 1994 |
[Effect of apressin, obsidan, diprazine and their combination on the concentration of NAD and NADH2 in the liver and brain of hypoxic rats].
Topics: Acute Disease; Animals; Brain Chemistry; Drug Combinations; Female; Hydralazine; Hypoxia; Liver; NAD | 1978 |
Regression of ventricular hypertrophy abolishes cardiocyte vulnerability to acute hypoxia.
Topics: Animals; Blood Gas Analysis; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Heart; Hemodynami | 1990 |
Neonatal nutritional deprivation or enhancement: the cardiac-sympathetic axis and its role in cardiac growth and stress responses.
Topics: Age Factors; Animals; Animals, Newborn; Female; Heart; Hydralazine; Hypoxia; Isoproterenol; Male; My | 1988 |
Continuous, low dose of hydralazine, reduces acute hypoxic pulmonary hypertension without a corresponding fall in systemic arterial pressure.
Topics: Animals; Blood Pressure; Female; Hydralazine; Hypertension, Pulmonary; Hypoxia; Male; Sheep | 1986 |